CD8A and non-small cell lung carcinoma: Autologous dendritic cell-derived exosomes with improved immunostimulatory function have been tested in a phase II clinical trial for the activation of CD8+ T cells [91] in non-small cell lung cancer (NSCLC) patients, observing disease stabilisation and a better overall survival [92].